{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-275395","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.188353+00:00","generated_at":"2026-06-08T05:36:07.345989+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IO Biotech Q3 net loss $21.7M, cash $165.5M; Phase 3 melanoma trial fully enrolled","bullets":["Net loss $21.7M in Q3 2023 vs $15.7M Q3 2022; R&D expenses $17.7M (up from $10.0M) driven by Phase 3 trial.","Cash and equivalents $165.5M at Sept 30, 2023, including $75M private placement; cash runway into Q4 2025.","Completed enrollment of 380 patients in pivotal Phase 3 (IO102-IO103 + pembrolizumab) for advanced melanoma; interim ORR expected Q3 2024, PFS H2 2025.","Appointed Helen Collins, MD to board; she serves as Chair of R&D Committee and brings extensive oncology drug development experience.","Presented encouraging preliminary Phase 2 data at WCLC and ESMO; three non-clinical posters at SITC 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-275395","json":"https://secwatch.observer/filing/0001193125-23-275395.json","markdown":"https://secwatch.observer/filing/0001193125-23-275395.md","text":"https://secwatch.observer/filing/0001193125-23-275395.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523275395/0001193125-23-275395-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523275395/d893930d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:36:07.345989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f02f1e81a19399f9e66798287bc3c1ec69228e0","claim":"IO Biotech, Inc. reported the quarter ended September 30, 2023 results: net income $21.7 million.","evidence_excerpt":"Net loss for the three months ended September 30, 2023, was $21.7 million, compared to $15.7 million for the three months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523275395/0001193125-23-275395-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"$21.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fce569b58e","claim":"Helen Collins was appointed as Class II Director at IO Biotech, Inc..","evidence_excerpt":"On November 9, 2023, the Company increased the size of the Board from seven to eight directors, and appointed Helen Collins, M.D. as a Class II director of the Company to fill the vacancy, effective as of that same date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523275395/0001193125-23-275395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}